[1]
|
N. Braun, A. Schweisfurth, C. Lohofener, et al., “Epidemiology of Glomerulonephritis in Northern Germany,” International Urology and Nephrology, Vol. 43, No. 4, 2011, pp. 1117-1126.
doi:10.1007/s11255-011-9955-4
|
[2]
|
Council of the European Union, “Council Recommendation on an Action in the Field of Rare Diseases,” Interinstitutional File 2008/0218 (CNS).
|
[3]
|
U. Frei and H.-J. Schober-Halstenberg, “Nierenersatztherapie in Deutschland 2006/2007,” Quasi-Niere gGmbH, Sch?neberg, 2008.
|
[4]
|
K. Farrington, A. Hodsman, A. Casula, D. Ansell and J. Feehally, “UK Renal Registry 11th Annual Report (December 2008): Chapter 4 ESRD Prevalent Rates in 2007 in the UK: National and Centre-Specific Analyses,” Nephron Clinical Practice, Vol. 111, Suppl. 1, 2009, pp. c43-c68
|
[5]
|
S. C. Chen, “United States Renal Data System—the concise 2008 annual data report,” 2008. www.usrds.org.
|
[6]
|
A. Rüther, H. P. Dauben and H. Schweim, “Die Deutsche Agentur für Health Technology Assessment (HTA) Beim DIMDI (DAHTA@DIMDI),” Bundesgesundheitsbl-Ge- sundheitsforsch-Gesundheitsschutz, Vol. 44, No. 9, 2001, pp. 865-869.
|
[7]
|
S. C. Palmer, K. Nand and G. F. Strippoli, “Interventions for Minimal Change Disease in Adults with Nephrotic Syndrome,” Cochrane Database of Systematic Reviews, Vol. 23, No. 1, D001537.
|
[8]
|
C.-K. Yeung, K.-L. Wong and W. L. Ng, “Intravenous Methylprednisolone Pulse Therapy in Minimal Change Nephrotic Syndrome,” Australian and New Zealand Jour- nal of Medicine, Vol. 13, No. 4, pp. 349-351.
doi:10.1111/j.1445-5994.1983.tb04479.x
|
[9]
|
E. M. Hodson, N. S. Willis and J. C. Craig, “Corticosteroid Therapy for Nephrotic Syndrome in Children,” Cochrane Database of Systematic Reviews, No. 4, 2007, CD001533.
|
[10]
|
E. M. Hodson, D. Habashy and J. C. Craig, “Interventions for Idiopathic Steroid-Resistant Nephrotic Syndrome in Children,” Cochrane Database of Systematic Reviews, Vol. 19, No. 2, 2006, CD003594
|
[11]
|
E. M. Hodson, N. S. Willis and J. C. Craig, “Non-Corticosteroid Treatment for Nephrotic Syndrome In Children,” Cochrane Database of Systematic Reviews, No. 4, 2008, CD002290
|
[12]
|
N. Braun, F. Schmutzler, C. Lange, et al., “Immunosuppressive Treatment for Focal Segmental Glomerulosclerosis in Adults (Review), Non-Corticosteroid Treatment for Nephrotic Syndrome in Children,” Cochrane Database of Systematic Reviews, No. 3, 2008, CD003233.
|
[13]
|
G. Banfi, M. Moriggi, E. Sabadini, G. Fellin, G. D’Amico and C. Ponticelli, “The Impact of Prolonged Immunosup- pression on the Outcome of Idiopathic Focal-Segmental Glomerulosclerosis with Nephrotic Syndrome in Adults. A Collaborative Retrospective Study,” Clinical Nephrology, Vol. 36, No. 2, 1991, pp. 53-59.
|
[14]
|
J. A. Samuels, G. F. Strippoli, J. C. Craig, F. P. Schena and D. A. Molony, “Immunosuppressive Agents for Treating IgA Nephropathy,” Cochrane Database of Systematic Reviews, No. 4, 2003, CD003965.
|
[15]
|
J. Floege and H. J. Grone, “IgA-Nephropathie,” Der Internist, Vol. 44, No. 9, 2002, pp. 1131-1139.
doi:10.1007/s00108-003-1026-1
|
[16]
|
C. Pozzi, P. G. Bolasco, G. B. Fogazzi, et al., “Corticosteroids in IgA Nephropathy: A Randomised Controlled Trial,” Lancet, Vol. 353, No. 9156, 1999, pp. 883-887.
doi:10.1016/S0140-6736(98)03563-6
|
[17]
|
F. W. Ballardie and I. S. D. Roberts, “Controlled Prospective Trial of Prednisolone and Cytotoxis in Progressive IgA Nephropathy,” Journal of the American Society of Nephrology, Vol. 13, No. 1, 2002, pp. 42-148.
|
[18]
|
A. Schieppati, A. Perna, J. Zamora, G. A. Giuliano, N. Braun and G. Remuzzi, “Immunosuppressive Treatment for Idiopathic Membranous Nephropathy in Adults with Nephrotic Syndrome,” Cochrane Database of Systematic Reviews, No. 4, 2004, CD004293.
|
[19]
|
D. Cattran, “Management of Membranous Nephropathy: When and What for Treatment,” Journal of the American Society of Nephrology, Vol. 16, No. 5, 2005, pp. 1188-1194. doi:10.1681/ASN.2005010028
|
[20]
|
C. Ponticelli, P. Altieri, F. Scolari, et al., “A Randomized Study Comparing Methylprednisolone Plus Chlorambucil versus Methylprednisolone Plus Cyclophosphamide in Idiopathic Membranous Nephropathy,” Journal of the American Society of Nephrology, Vol. 9, No. 3, 1998, pp. 444-450.
|
[21]
|
G. Walters, N. S. Willis and J. C. Craig, “Interventions for Renal Vasculitis in Adults,” Cochrane Database of Systematic Reviews, No. 3, 2008, CD003232.
|
[22]
|
American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines, “Guidelines for Referral and Management of Systemic Lupus Erythematosus in Adults,” Arthritis & Rheumatism, Vol. 42, 1999, pp. 1785-1796.
|
[23]
|
R. S. Flanc, M. A. Roberts, G. F. Strippoli, S. J. Chadban, P. G. Kerr and R. C. Atkins, “Treatment for Lupus Nephritis,” Cochrane Database of Systematic Reviews, No. 1, 2004, CD002922.
|
[24]
|
C. S. Wilcox, “New Insights into Diuretic Use in Patients with Chronic Renal Disease,” Journal of the American Society of Nephrology, Vol. 13, No. 2002, pp. 798-805.
|
[25]
|
G. Maschio, D. Alberti, F. Locatelli, et al., “Angiotensin-Converting Enzyme Inhibitors and Kidney Protection: The AIPRI Trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group,” Journal of Cardiovascular Pharmacology, Vol. 33, Suppl. 1, 1999, pp. S16-S20. doi:10.1097/00005344-199900001-00004
|
[26]
|
D. Cox, “Regression Models and Life Tables,” Journal of the Royal Statistical Society. Series B, Vol. 34, No. 2, 1972, pp. 187-220.
|
[27]
|
R. Muecke, O. Micke, B. Reichl, et al., “Demographic, Clinical and Treatment Related Predictors for Event-Free Probability Following Low-Dose Radiotherapy for Painful Heel Spurs—A Retrospective Multicenter Study of 502 Patients,” Acta Oncologica, Vol. 46, No. 2, 2007, pp. 239-246. doi:10.1080/02841860600731935
|
[28]
|
D. L. Sackett, S. E. Straus, W. S. Richardson, W. Rosenberg and R. B. Haynes, “Evidence-Based Medicine: How to Practic and Teach EBM,” Churchill Livingstone, Edinburgh, 2000.
|
[29]
|
A. Bohle, S. Mackensen-Haen and G. H. Von, “Signifi- cance of Tubulointerstitial Changes in the Renal Cortex for the Excretory Function and Concentration Ability of the Kidney: A Morphometric Contribution,” American Journal of Nephrology, Vol. 7, No. 6, 1987, pp. 421-433.
doi:10.1159/000167514
|
[30]
|
D. C. Cattran, R. Coppo, H. T. Cook, et al., “The Oxford Classification of IgA Nephropathy: Rationale, Clinicopathological Correlations, and Classification,” Kidney International, Vol. 76, No. 5, 2009, pp. 534-545.
doi:10.1038/ki.2009.243
|
[31]
|
“Safety and Tolerability of Cyclosporin a (Sandimmun) in Idiopathic Nephrotic Syndrome. Collaborative Study Group of Sandimmun in Nephrotic Syndrome,” Clinical Nephrology, Vol. 35, Suppl. 1, 1991, pp. S48-S60
|
[32]
|
D. C. Cattran, G. B. Appel, L. A. Hebert, et al., “A Randomized Trial of Cyclosporine in Patients with Steroid-Resistant Focal Segmental Glomerulosclerosis. North America Nephrotic Syndrome Study Group,” Kidney International, Vol. 56, 1999, pp. 2220-2226.
doi:10.1046/j.1523-1755.1999.00778.x
|
[33]
|
E. Imbasciati, R. Gusmano, A. Edefonti, et al., “Controlled Trial of Methylprednisolone Pulses and Low Dose Oral Prednisone for the Minimal Change Nephrotic Syndrome,” British Medical Journal (Clinical Research Ed.), Vol. 291, No. 6505, 1985, pp. 1305-1308.
doi:10.1136/bmj.291.6505.1305
|
[34]
|
D. J. Wallace, D. Goldfinger, G. Savage, et al., “Predictive Value of Clinical, Laboratory, Pathologic, and Treatment Variables in Steroid/Immunosuppressive Resistant Lupus Nephritis,” Journal of Clinical Apheresis, Vol. 4, No. 1, 1988, pp. 30-34. doi:10.1002/jca.2920040107
|
[35]
|
D. R. Jayne, G. Gaskin, N. Rasmussen, et al., “Randomized Trial of Plasma Exchange or High-Dosage Methylprednisolone as Adjunctive Therapy for Severe Renal Vasculitis,” Journal of the American Society of Nephrology, Vol. 18, No. 7, 2007, pp. 2180-2188.
doi:10.1681/ASN.2007010090
|
[36]
|
NKF K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease,” American Journal of Kidney Diseases, Vol. 43, Suppl. 291, 2004, pp. S1-S290.
doi:10.1053/S0272-6386(04)00369-5
|